Boundless Bio Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on the stock and has a $4.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Mitchell Kapoor has given his Buy rating due to a combination of factors that highlight the potential of Boundless Bio Inc.’s innovative approach to cancer treatment. The company’s combination of CHK1 and RNR inhibitors, BBI-825 and BBI-355, has demonstrated significant anti-tumor activity in preclinical models, particularly in gastric and small cell lung cancer. This combination has shown the ability to achieve efficacy at doses that avoid the severe side effects that have hindered previous CHK1 inhibitors.
Furthermore, the strategy of targeting ecDNA-driven synthetic lethality presents a novel opportunity that distinguishes Boundless Bio from other DNA damage response efforts. The company’s approach aims to decouple efficacy from hematologic toxicity, which has been a major challenge for similar programs in the past. The potential for broad applicability across various tumor types and the company’s guidance towards achieving proof-of-concept within its current cash runway further support the Buy rating. Kapoor’s confidence is also reflected in the 12-month price target of $4 per share, emphasizing the promising outlook for Boundless Bio’s clinical advancements.
According to TipRanks, Kapoor is a 3-star analyst with an average return of 3.5% and a 43.81% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Halozyme, and Summit Therapeutics.